The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 615-621

  Tsumura, R ^a   Ikawa, Kazuro ^a   Morikawa, N ^a   Ikeda, K ^a   Shibukawa, M ^a   Iida, K ^a   Kurisu, K ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Monte Carlo simulation; Population pharmacokinetics; Probability of target attainment

Indexed keywords

MEROPENEM;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MENINGITIS; BACTERIUM ISOLATE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG INFUSION; DRUG PENETRATION; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; JAPAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEISSERIA MENINGITIDIS; NEUROSURGERY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; STREPTOCOCCUS PNEUMONIAE; SURGICAL PATIENT; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS BLOOD;

EID: 57049121314     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.615     Document Type: Article

References (22)

1. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.
2. Weisfelt M, de Gans J, van de Beek D. Bacterial meningitis: a review of effective pharmacotherapy. Expert Opin Pharmacother 2007;8:1493-504.
3. Dagan R, Velghe L, Rodda JL, Klugman KP. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994;34:175-9.
4. Nau R, Lassek C, Kinzig-Schippers M, Thiel A, Prange HW, Sbrgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 1998;42:2012-6.
5. Nicasio AM, Quintiliani R Jr, DeRyke CA, Kuti JL, Nicolau DP. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. Ann Pharmacother 2007;41:1077-81.
6. Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother 2007;60:1038-44.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
8. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
9. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006;354:44-53.
10. Tzanakaki G, Mastrantonio P. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J Antimicrob Agents 2007;29:621-9.
11. Santos LC, Simões J, Severo M, Vazquez J, Lecour H. Bacterial meningitis in an urban area: etiologic study and prognostic factors. Infection 2007;35:406-13.
12. Ikeda K, Ikawa K, Morikawa N, Miki M, Nishimura S, Kobayashi M. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:371-5.
13. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981;4:879-85.
14. Ikawa K, Morikawa N, Hayato S, Ikeda K, Ohge H, Sueda T. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. Int J Antimicrob Agents 2007;30:270-3.
15. Ikawa K, Morikawa N, Matsuda S, et al. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients. Int J Antimicrob Agents 2007;30:352-5.
16. Yamaguchi K, Murakami M, Takahashi A, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004. Jpn J Antibiot 2005;58:655-89.
17. Watanabe Y, Takahashi C, Ohya H, Okazaki N, Onoue Y. Antibiotic susceptibility of Neisseria meningitidis from healthy and diseased persons in Japan. Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 2007;81:669-74.
18. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-7.
19. Burgess DS, Frei CR, Lewis Ii JS, Fiebelkorn KR, Jorgensen JH. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect 2007;13:33-9.
20. Turner PJ. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study. Diagn Microbiol Infect Dis 2005;53:273-9.
21. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinat fluid. Clin Infect Dis 1998;27:1117-27.
22. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999;13:595-618.